As of June 2022 we do not know what the future plans are for Tirzepatide and a UK launch. It is likely that the US market will be used as a test for the future of Tirzepatide, first as a type 2 diabetes medicine then as an obesity medicine to assist weight loss. Eli Lilly is a well established global pharmaceutical manufacturer and the company will see no reason not to access other markets if Tirzepatide continues to show good support for weight loss and the relevant authorities are happy to license the drug for that purpose.
There isn't a fixed timeline for the launch of medicines in the UK market and this is determined by the manufacturer and then the MHRA’s time to grant a license. Typically the MHRA will seek to make a decision on a license within 150 days of an application. On this basis it is unlikely that the UK will see Tarazepide available until late 2023 at the earliest and this may only be as medication for type 2 diabetes.